Search
for
Sort by
Research 61–90 of 652
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications
- Guidelines for perioperative antithrombotic therapy in hair restoration surgery: management of patients with coronary heart disease, mechanical heart valve, and atrial fibrillation
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population
- Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
- Rumpel-Leede Phenomenon Associated with Pneumatic Compression: A Case Report
- Thrombophilia and Polycythemia in a Woman With Budd-Chiari Syndrome
- Topical imiquimod—Be aware of the unexpected
- Efficacy and safety of autologous adipose-derived stromal vascular fraction enriched with platelet-rich plasma in flap repair of transsphincteric cryptoglandular fistulas
- Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Ritlecitinib in severe alopecia areata: a profile of its use
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Ischemic Stroke in a Young Adult Male During Finasteride Therapy
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Hormonal Influences on Women's Health and Athletic Performance: Insights into the Menstrual Cycle, Menopause, Contraception, and Anabolic Steroids
- Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report
- Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
- Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain
- Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practice
- Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib